01 May 26
Early development is one of the most important and least forgiving stages in drug development. The decisions made before a programme reaches the clinic can have lasting implications for safety, dosing, study design and long-term success. Moving from preclinical science into first-in-human studies requires not only strong data, but also pragmatic decision-making, early regulatory engagement and the right expertise around the table.
Early Decisions Shape Long-Term Success
Early development is the foundation of every programme. Choices made at the preclinical stage determine whether later studies can achieve their potential, and even relatively small missteps can create significant downstream consequences.
Smaller errors can snowball. Producing too little drug substance today may mean under-dosing in Phase 1, leading to inconclusive results in Phase 2.
Foundations first. Early work sets the safety profile, target dose range and Target Product Profile, all of which are critical for success.
Pragmatism over perfection. There are rarely perfect decisions in early development, so companies must weigh the available evidence and move forward with confidence.
Getting early decisions right helps avoid costly missteps and keeps the path to patients clear.
Regulators Are Partners, Not Gatekeepers
Regulatory engagement should not be treated as a hurdle to clear late in development. The strongest programmes view regulators as collaborators from the outset and use early dialogue to strengthen their plans.
Engage early. Early conversations on toxicology, CMC and study design can reduce the risk of delays.
Plan for adaptability. Especially for antibodies and oligonucleotides, adaptive protocols informed by regulatory input can help address unknown PK/PD profiles.
Save time and resources. Proactive dialogue helps small biotechs avoid expensive amendments that can burn through cash reserves.
Treating regulators as allies helps teams build smarter, faster and more resilient programmes.
The Right Team, Making the Right Decisions
Success depends not just on science, but on the people and structures guiding it. Strong early development requires phase-appropriate expertise, shared accountability and the confidence to make timely decisions.
Get phase-appropriate expertise. Early development physicians bring a unique perspective that differs from late-stage medical affairs or development physicians.
Encourage cross-functional dialogue. Avoid hub-and-spoke consulting models — teams need to share accountability and align on strategy.
Make decisions and own them. Decision paralysis slows progress, while pragmatic and timely choices help maintain momentum.
The right mix of expertise, alignment and accountability is what moves science from bench to bedside.
Key Insight
Early development is where promising science becomes practical medicine. By making smart early choices, partnering with regulators and empowering cross-functional teams, biotech and pharma innovators can reduce risk and accelerate progress towards patient impact.
Contact Us
tranScrip supports biotechs at every stage of development. So wherever you are in the product lifecycle, get in touch today — our experts are ready to guide you.
Hear more in Episode 2 of tranScrip Talks, where Chris Floyd, Executive Medical Director, Early Development, and Rob Fox, Chief Commercial Officer, discuss what it really takes to get ready for clinic.
Get in touch to see how our senior cross-functional experts can help you reduce risk, protect value, and move forward with confidence.